Baseline in vitro activities of the antimalarials pyronaridine and methylene blue against Plasmodium falciparum isolates from Kenya

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 1105-1107

  Okombo, John ^a   Kiara, Steven M ^a   Mwai, Leah ^a   Pole, Lewa ^a   Ohuma, Eric ^a   Ochola, Lynette Isabella ^a   Nzila, Alexis ^a,b  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ; METHYLENE BLUE; PIPERAQUINE; PYRONARIDINE;

ANTIMALARIAL ACTIVITY; ARTICLE; CODON; HUMAN; IN VITRO STUDY; KENYA; METHEMOGLOBINEMIA; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SIDE EFFECT; URINE COLOR;

ANIMALS; ANTIMALARIALS; HUMANS; KENYA; MALARIA, FALCIPARUM; METHYLENE BLUE; NAPHTHYRIDINES; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC; PROTOZOAN PROTEINS;

EID: 84856068996     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05454-11     Document Type: Article

References (32)

1. Ademowo OG, Nneji CM, Adedapo AD. 2007. In vitro antimalarial activity of methylene blue against field isolates of Plasmodium falciparum from children in Southwest Nigeria. Indian J. Med. Res. 126:45- 49.
2. Anonymous. 15 October 2010. Global malaria portfolio, 3Q 2010, classified by therapeutic type. Medicines for Malaria Venture, Geneva, Switzerland. http://www.mmv.org/sites/default/files/uploads/docs/essential-info-for- scientists/3Q-Global-Malaria-Portfolio-Slide-by-therapeutic-type.ppt.
3. Bountogo M, et al. 2010. Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso. Trop. Med. Int. Health 15:713-717.
4. Chen C, Zheng X. 1992. Development of the new antimalarial drug pyronaridine: a review. Biomed. Environ. Sci. 5:149-160.
5. Clifton J, II, Leikin JB. 2003. Methylene blue. Am. J. Ther. 10:289-291.
6. Coulibaly B, et al. 2009. Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS One 4:e5318.
7. Dondorp AM, et al. 2010. Artemisinin resistance: current status and scenarios for containment. Nat. Rev. Microbiol. 8:272-280.
8. Kokwaro G, Mwai L, Nzila A. 2007. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin. Pharmacother 8:75-94. (Pubitemid 46070831)
9. Kurth F, et al. 2009. In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays. Malar. J. 8:79.
10. Mandi G, et al. 2005. Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Trop. Med. Int. Health 10:32-38. (Pubitemid 40193683)
11. Meissner PE, et al. 2005. Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]. Malar. J. 4:45.
12. Mutabingwa TK, et al. 2009. Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania. PLoS One 4:e5138.
13. Mwai L, et al. 2009. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob. Agents Chemother. 53:5069-5073.
14. Mwai L, et al. 2009. Chloroquine resistance before and after its withdrawal in Kenya. Malar. J. 8:106.
15. Okombo J, et al. 2010. In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya. Antimicrob. Agents Chemother. 54:3302-3307.
16. Okombo J, Ohuma E, Picot S, Nzila A. 2011. Update on genetic markers of quinine resistance in Plasmodium falciparum. Mol. Biochem. Parasitol. 177:77-82.
17. Pascual A, et al. 2011. In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs. Antimicrob. Agents Chemother. 55:2472-2474.
18. Poravuth Y, et al. 2011. Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One 6:e14501.
19. Pradines B, et al. 2010. Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum. Malar. J. 9:339.
20. Pradines B, et al. 1999. In vitro susceptibility of African isolates of Plasmodium falciparum from Gabon to pyronaridine. Am. J. Trop. Med. Hyg. 60:105-108. (Pubitemid 29066013)
21. Pradines B, et al. 1998. In-vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents. J. Antimicrob. Chemother. 42:333-339. (Pubitemid 28442447)
22. Pradines B, et al. 2006. In vitro activity of iron-binding compounds against Senegalese isolates of Plasmodium falciparum. J. Antimicrob. Chemother. 57:1093-1099. (Pubitemid 44644410)
23. Price RN, et al. 2010. In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax. Antimicrob. Agents Chemother. 54:5146-5150.
24. Ramharter M, et al. 2008. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J. Infect. Dis. 198:911-919.
25. Ringwald P, Bickii J, Basco LK. 1998. Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. Clin. Infect. Dis. 26:946-953. (Pubitemid 28180335)
26. Ringwald P, Eboumbou EC, Bickii J, Basco LK. 1999. In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against Plasmodium falciparum. Antimicrob. Agents Chemother. 43:1525-1527. (Pubitemid 29259362)
27. Sasi P, et al. 2009. In vivo and in vitro efficacy of amodiaquine against Plasmodium falciparum in an area of continued use of 4-aminoquinolines in East Africa. J. Infect. Dis. 199:1575-1582.
28. Schirmer RH, et al. 2003. Methylene blue as an antimalarial agent. Redox Rep. 8:272-275. (Pubitemid 38035586)
29. Sirima SB, Gansane A. 2007. Artesunate-amodiaquine for the treatment of uncomplicated malaria. Expert Opin. Invest. Drugs 16:1079-1085. (Pubitemid 47074162)
30. Some AF, et al. 2010. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob. Agents Chemother. 54:1949-1954.
31. Tshefu AK, et al. 2010. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 375:1457-1467.
32. Zoungrana A, et al. 2008. Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from burkina faso. PLoS One 3:e1630.